Clinical Study
Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
Table 3
GI AEs cumulative incidence and the probability that each treatment is associated with highest incidence.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EX5BID: exenatide 5 μg twice daily; EX10BID: exenatide 10 μg twice daily; EX2QW: exenatide 2 mg once weekly; LIR0.6: liraglutide 0.6 mg once daily; LIR1.2: liraglutide 1.2 mg once daily; LIR1.8: liraglutide 1.8 mg once daily. Ranking: probability of being the worst treatment, of being the second worst, the third worst and so on, among the 8 comparisons. CT: conventional treatment. SUCRA: surface under the cumulative ranking curve. |